Vilin Bio Med Limited (NSE:VILINBIO)
41.10
0.00 (0.00%)
Aug 20, 2026, 3:12 PM IST
Vilin Bio Med Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 573 | 511 | 285 | 265 | - | - | |
Market Cap Growth | 61.18% | 79.66% | 7.37% | - | - | - |
Enterprise Value | 561 | 515 | 297 | 255 | - | - |
Last Close Price | 41.10 | 36.65 | 20.40 | 19.00 | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 30.00 | 26.51 | 127.33 | 163.21 | - | - |
PS Ratio | 1.36 | 1.21 | 1.92 | 1.68 | - | - |
PB Ratio | 2.02 | 1.80 | 1.23 | 1.16 | - | - |
P/TBV Ratio | 2.02 | 1.80 | 1.23 | 1.16 | - | - |
P/FCF Ratio | 142.91 | 127.44 | - | - | - | - |
P/OCF Ratio | 82.14 | 73.25 | 130.84 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.33 | 1.22 | 2.00 | 1.61 | - | - |
EV/EBITDA Ratio | 17.56 | 16.13 | 37.70 | 31.22 | - | - |
EV/EBIT Ratio | 19.28 | 17.70 | 43.47 | 37.14 | - | - |
EV/FCF Ratio | 139.76 | 128.35 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.11 | 0.30 | 0.46 | 0.72 |
Debt / EBITDA Ratio | 0.06 | 0.06 | 3.27 | 8.36 | 1.90 | 6.88 |
Debt / FCF Ratio | 0.51 | 0.51 | - | - | - | 25.39 |
Net Debt / Equity Ratio | -0.04 | -0.04 | 0.11 | 0.03 | 0.46 | 0.71 |
Net Debt / EBITDA Ratio | -0.40 | -0.40 | 3.20 | 0.96 | 1.89 | 6.83 |
Net Debt / FCF Ratio | -3.15 | -3.15 | -1.85 | -0.10 | -2.90 | 25.21 |
Asset Turnover | 1.35 | 1.35 | 0.49 | 0.63 | 0.79 | 0.82 |
Inventory Turnover | 6.47 | 6.47 | 3.04 | 4.88 | 4.59 | 4.13 |
Quick Ratio | 2.71 | 2.71 | 1.39 | 1.26 | 0.87 | 1.63 |
Current Ratio | 4.25 | 4.25 | 2.75 | 2.01 | 1.24 | 2.22 |
Return on Equity (ROE) | 7.50% | 7.50% | 0.97% | 0.97% | 13.78% | 0.46% |
Return on Assets (ROA) | 5.80% | 5.80% | 1.42% | 1.71% | 9.72% | 2.51% |
Return on Invested Capital (ROIC) | 7.28% | 7.50% | 2.03% | 2.53% | 12.03% | 3.25% |
Return on Capital Employed (ROCE) | 10.20% | 10.20% | 2.90% | 3.00% | 21.70% | 6.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.36% | 3.77% | 0.78% | 0.61% | - | - |
FCF Yield | 0.70% | 0.78% | -4.77% | -28.00% | - | - |
Buyback Yield / Dilution | -0.92% | -0.92% | - | -40.20% | -20.61% | - |